Cost effectiveness of pegylated interferon alpha 2b and ribavirin combination in chronic hepatitis C [5]

Gut

Volumn 52, Issue 10, 2003, Pages 1532-

  Poynard, T ^a  

^a Pitie Salpetriere 47 83   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN; THYROTROPIN; THYROXINE; VIRUS DNA;

COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC APPROACH ROUTE; DNA DETERMINATION; DRUG COST; HEPATITIS C; HORMONE DETERMINATION; HOSPITALIZATION; HUMAN; LETTER; LIVER BIOPSY; PREGNANCY TEST; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; UNITED STATES;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 0141869032     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.10.1532     Document Type: Letter

References (3)

1. Wong JB, Bennett WG, Koff RS, et al. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA 1998;280:2088-93.
2. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-75.
3. Halfon P, Imbert-Bismut F, Messous D, et al. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comparative Hepatology 2002;2:3.